Mitral Valve Repair Center

The Ross procedure using bicuspid and quadricuspid pulmonary valves

Pablo Filippa, Vincent Chauvette, Walid Ben Ali, Raymond Cartier, Nancy Poirier, Ismail El-Hamamsy, Philippe Demers

Central MessageIn select patients with bicuspid or quadricuspid pulmonary autograft, good mid-term outcomes and valve function can be achieved. Careful valve analysis and implantation are of utmost importance.Read full publication >

Mitral Valve Intervention in Elderly or High-Risk Patients: A Review of Current Surgical and Interventional Management

Maheedhar Gedela, Busra Cangut, Lucy Safi, Parasuram Krishnamoorthy, Dimosthenis Pandis, Ahmed El-Eshmawi, Gilbert H L Tang

AbstractMitral regurgitation is a prevalent valvular disease, and its management has gained increasing importance because of the aging population. Although traditional surgery remains the gold standard, the field of transcatheter therapies, including transcatheter edge-to-edge repair an...

Heparin-induced thrombocytopaenia complicating cardiogenic shock requiring durable mechanical circulatory support: a case report

Peter Cangialosi, Francine Dembitzer, Anelechi C Anyanwu, Aditya Parikh

AbstractBackground: Heparin-induced thrombocytopaenia (HIT) is an immune-mediated reaction to heparin therapy that may lead to life-threatening thrombotic events. This disorder complicates intraoperative heparin use during left ventricular assist device (LVAD) implantation.Case summary:...

HeartMate-3 Ventricular Assist Devices Versus the Total Artificial Heart for Biventricular Support: A Single-Center Series

Mohan Satish, Anelechi Anyanwu, Noah Moss, Anuradha Lala, Shinobu Itagaki, Julie Roldan, Donna Mancini

AbstractIntroduction: The SynCardia total artificial heart (TAH) is the only device approved for biventricular support. Continuous flow ventricular assist devices (VAD) in a biventricular configuration (BiVAD) have been used with variable results. The purpose of this report was to exami...

Complex Repair of Anomalous Left Coronary Artery From the Pulmonary Artery in a 55-Year-Old Patient

Timothy Lee, Jennifer L Cohen, Alice Chan, Ali N Zaidi, Percy Boateng, Raghav A Murthy

AbstractAnomalous left coronary artery from the pulmonary artery (ALCAPA) is a congenital malformation that classically presents within the first year of life. Few patients survive into adulthood, and initial presentation after the fourth decade of life is rare. We describe a 55-year-ol...

Tricuspid Clip Might Work for More Patients Than Thought

Study shows better-than-expected benefit for expanded criteria cohortby Crystal PhendTricuspid transcatheter edge-to-edge repair (T-TEER) performed better than anticipated in patients expected to have only a modest benefit due to more complex anatomy, the TRILUMINATE trial showed.After ...

More TRILUMINATE Patients Flesh Out Tricuspid TEER’s Impact

The data further confirm the safety and efficacy of the device and add to better understanding of patient selection, researchers say.By Yael L. Maxwell Tricuspid-valve transcatheter edge-to-edge repair (TEER) using the TriClip system (Abbott) remains safe and effective in patients with ...

FDA Clears TriClip for Tricuspid Regurgitation

The US Food and Drug Administration (FDA) has approved Abbott's TriClip Transcatheter Edge-to-Edge Repair (TEER) system to repair severe tricuspid regurgitation (TR), the company has announced. By Megan BrooksThe approval follows the recent vote in favor of TriClip by the FDA Circulator...

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

Panel of independent experts reviewed data from the TRILUMINATE pivotal trial demonstrating safety, effectiveness and quality-of-life benefits of the TriClip systemAbbott announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the U.S. Food and ...

FDA Panel Takes a Positive View of TriClip in Tricuspid Regurgitation

The advisory committee took a hard look at the TRILUMINATE data and concluded the benefits of TriClip outweigh the risks.By Michael O'RiordanExpert advisors to the US Food and Drug Administration offered little in the way of pushback against the TriClip (Abbott) transcatheter edge-to-ed...